These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 8089068)
1. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. Chen HY; Livermore DM J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068 [TBL] [Abstract][Full Text] [Related]
2. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. Livermore DM; Yang YJ J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657 [TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance. Chen HY; Livermore DM J Antimicrob Chemother; 1994 Mar; 33(3):453-64. PubMed ID: 8040111 [TBL] [Abstract][Full Text] [Related]
4. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. Livermore DM; Chen HY J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs. Sader HS; Jones RN Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307 [TBL] [Abstract][Full Text] [Related]
6. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases]. Martínez-Beltrán J; Calderón C; Sierra MP; Alvarez M; Cantón R Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065 [TBL] [Abstract][Full Text] [Related]
7. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. Yang Y; Bhachech N; Bush K J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785 [TBL] [Abstract][Full Text] [Related]
8. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase. Minami S; Akama M; Araki H; Watanabe Y; Narita H; Iyobe S; Mitsuhashi S J Antimicrob Chemother; 1996 Mar; 37(3):433-44. PubMed ID: 9182100 [TBL] [Abstract][Full Text] [Related]
9. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2. Fung-Tomc JC; Gradelski E; Kolek B; Minassian B; Pucci M; Kessler RE; Bonner DP Antimicrob Agents Chemother; 1995 Feb; 39(2):386-93. PubMed ID: 7726503 [TBL] [Abstract][Full Text] [Related]
10. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. Livermore DM; Yang YJ J Infect Dis; 1987 Apr; 155(4):775-82. PubMed ID: 3102630 [TBL] [Abstract][Full Text] [Related]
11. [Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa]. Hiraishi T; Miyata A; Takata T; Araake M; Ogawa H; Gotoh N; Nishino T Jpn J Antibiot; 2002 Feb; 55(1):67-76. PubMed ID: 11977922 [TBL] [Abstract][Full Text] [Related]
12. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Livermore DM Antimicrob Agents Chemother; 1992 Sep; 36(9):2046-8. PubMed ID: 1329641 [TBL] [Abstract][Full Text] [Related]
13. Interactions of meropenem with class I chromosomal beta-lactamases. Yang YJ; Livermore DM J Antimicrob Chemother; 1989 Sep; 24 Suppl A():207-17. PubMed ID: 2808208 [TBL] [Abstract][Full Text] [Related]
14. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. Satake S; Yoneyama H; Nakae T J Antimicrob Chemother; 1991 Aug; 28(2):199-207. PubMed ID: 1778851 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. Chen HY; Yuan M; Livermore DM J Med Microbiol; 1995 Oct; 43(4):300-9. PubMed ID: 7562993 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-beta-methyl carbapenem. Hazumi N; Fuse A; Matsuda K; Hashizume T; Sanada M Antimicrob Agents Chemother; 1995 Mar; 39(3):702-6. PubMed ID: 7793876 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria. Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731 [TBL] [Abstract][Full Text] [Related]
19. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Raimondi A; Traverso A; Nikaido H Antimicrob Agents Chemother; 1991 Jun; 35(6):1174-80. PubMed ID: 1656855 [TBL] [Abstract][Full Text] [Related]
20. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. Mushtaq S; Vickers A; Woodford N; Livermore DM J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]